Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases
Congratulations to SSPC investigator Prof. Anne Marie Healy at Trinity College Dublin, who is part of the Aer Therapeutics, Inc. team who have a Series A financing of $36 Million for an Innovative Mucolytic for the Treatment of Lung Diseases. The IP arose from collaboration between University of California, San Francisco, Trinity College Dublin and University College Dublin. Dr Fahy’s [UCSF] laboratory collaboratively developed AER-01 with Stefan Oscarson’s glycochemistry laboratory at UCD and Prof. Anne Marie Healy’s pharmaceutical technology laboratory TCD. Investors in this round were Canaan, OrbiMed and Hatteras Venture Partners.